LAUSR

I n d I a n J o u r n a l o f P a t h o l o g y a n d M I c r o b I o l o g y ¦ V o l u M e 6 3 ¦ I s s u e 1 ¦ J a n u a r y M a r c h 2 0 2 0 156 Bumbea H, et al. Report of the European myeloma network on multiparametric flow‐cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431‐8. 3. Flores‐Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016;90B:61‐72. 4. Landgren O, Owen RG. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B ClinCytom 2016;90:14‐20. 5. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540‐7. 6. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez‐López J, et al. High‐risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687‐91. 7. Bladé J, de Larrea CF, Rosiñol L. Extramedullary involvement in multiple myeloma. Haematologica 2012;97:1618‐9. 8. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol 2015:169;851‐8. 9. Dahl IMS, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273‐7. 10. Cui RT, Yu SY, Huang XS, Zhang JT, Li F, Pu CQ. The characteristics of ascites in patients with POEMS syndrome. Ann Hematol 2013;92:1661‐4. 11. Sahu KK, Yanamandra U, Gupta N, Varma S, Malhotra P. Myelomatous effusions in multiple myeloma: 5 year experience from a tertiary medical centre in north India. J Clin Oncol 2016;34. doi: 10.1200/JCO.2016.34.15_suppl.e19503. 12. Mateo G, Montalban MA, Vidriales M, Lahuerta JJ, Mateos MV, Gutiérrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high‐dose therapy. J Clin Oncol 2008;26:2737‐44. 13. Paris A, Nhan T, Cornet E, Perol JP, Malet M, Troussard X. Performance evaluation of the body fluid mode on the platform Sysmex XE‐5000 series automated hematology analyzer. Int J Lab Hematol. 2010;32:539‐47. 14. Zimmermann M, Otto C, Gonzalez JB, Prokop S, Ruprecht K. Cellular origin and diagnostic significance of high‐fluorescent cells in cerebrospinal fluid detected by the XE‐5000 hematology analyzer. Int J Lab Hematol 2013;35:580‐8. 15. Palumbo A, Avet‐Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863‐9.